Protalix BioTherapeutics, Inc. business relationships
Companies named in Protalix BioTherapeutics, Inc.’s 10-K filed 2026-03-18, and public companies whose annual reports name Protalix BioTherapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 9 / 100 Top 4% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Protalix BioTherapeutics, Inc.’s annual report 8
“Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration worldwide except for Brazil.” SEC filing
“We have licensed to Pfizer the global rights to market and sell Elelyso in all markets, excluding Brazil, pursuant to the Amended Pfizer Agreement.” SEC filing
“We have granted the marketing rights to Elelyso globally, excluding Brazil, to Pfizer through an exclusive licensing agreement.” SEC filing
“● risks relating to our ability to manage our relationship with our collaborators, distributors, and partners, including, but not limited to, Pfizer Inc., or Pfizer, and Chiesi Farmaceutici S.p.A., or Chiesi;” SEC filing
“Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.” SEC filing
“The Company has partnered with Chiesi Farmaceutici S.p.A. ("Chiesi") for the development and commercialization of Elfabrio through two exclusive global licensing and supply agreements.” SEC filing
“Exclusive License and Supply Agreement dated as of October 17, 2017, made by and between Protalix Ltd. and Chiesi Farmaceutici S.p.A.” SEC filing
“We are currently engaged in a collaborative research project with Secarna Pharmaceuticals GmbH & Co. KG, or Secarna, through which we are partnering in the discovery of novel antisense oligonucleotide (ASO) therapies against multiple targets for rare renal indications.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.